Paradoxes of the Humoral Immune Response against WNV
Humoral immunity limits WNV dissemination, as animals lacking antibodies develop high-grade viremia, early dissemination into the brain, and uniform mortality [4] . The envelope E glycoprotein is the major surface structural protein on the virion and the principal antigen that elicits neutralizing antibodies; as such, it is a primary target for vaccine development. New studies suggest and explain why the level of neutralizing antibodies in serum may not always correlate with protection against WNV.
WNV virions incorporate 180 E proteins on their surface. The E proteins of newly synthesized immature WNV are organized into trimeric spikes composed of pre-membrane (prM) and E protein heterodimers. During egress, immature virions undergo a maturation step in which a furin-like protease cleaves prM, resulting in a reorganization of E proteins into a distinct homodimeric array [5] . As complete maturation is not required for infectivity, WNV virions can be heterogeneous with respect to the level of prM on their surface. In theory, mature, partially mature, and mostly immature virions may be differentially recognized and neutralized by antibodies. Recent experiments establish that virion maturation impacts the sensitivity of WNV to antibody neutralization [6] . Antibodies that target the virus fusion peptide, which comprise a major component of the human antibody response following WNV infection or vaccination, do not neutralize the fully mature form of the virion.
Interestingly, some poorly neutralizing human antibodies against E may still be protective in vivo (M. Vogt, M. Throsby, and M. Diamond, unpublished data), presumably due to interactions with complement and/or Fc-c receptors. Furthermore, NS1, a non-structural glycoprotein that is absent from the virion but expressed on the surface of infected cells, elicits nonneutralizing protective antibodies that inhibit infection through both Fc-c receptor-dependent and -independent mechanisms [7] . Although both neutralizing and non-neutralizing antibodies contribute to humoral protection against WNV infection and possibly other flaviviruses, current vaccine programs judge the efficacy of the humoral response primarily on the magnitude of neutralizing antibodies measured in serum. The studies outlined above suggest that improved correlations with protection in vivo may be achieved if the maturation state of the virion, the functional profile of anti-NS1 antibodies, and effector mechanisms of antibodies are considered.
A Protective Cellular Immune Response against WNV in the Brain
For many encephalitic viruses, the cellular immune response in the central nervous system (CNS) can be pathologic, as injury to neurons or glial cells causes irreversible loss of function and death [8] . However, cellular immunity is absolutely required for clearance of infection by virulent North American WNV isolates.
Mice deficient in CD4
+ or CD8 + T cells develop persistent WNV infection in the brain [9, 10] , and humans with hematological malignancies and impaired T cell function are at increased risk of neuroinvasive WNV infection and poor outcome [11] . WNVspecific CD8
+ T cells secrete inflammatory cytokines and lyse virus-infected neurons through perforin-and Fas ligand-dependent mechanisms, whereas CD4
+ T cells sustain WNV-specific CD8 + T cell responses in the CNS that enable viral clearance [10] . This lytic and potentially destructive activity of WNV-specific CD8 + T cells in the brain is paradoxically protective because of the urgent need to limit replication of a highly cytopathic virus in neurons. Consistent with this, if mice are infected with a less pathogenic isolate of WNV, the CD8 + T cell response can be detrimental and cause excessive immunopathogenesis and injury [12] .
West Nile Virus and IFN: Regulation and CounterRegulation
The interferon (IFN) response is an essential host defense program that limits infection of many families of RNA and DNA viruses. IFN-a and -b are produced during the earliest stages of WNV infection after host cell recognition of viral RNA. Mammalian cells detect WNV viruses and induce IFN by recognizing single (ssRNA) or double-stranded (dsRNA) viral RNA through the endosomal Toll-like receptors 3 and 7 (TLR3 and TLR7), and the cytoplasmic proteins retinoic acid-inducible gene I (RIG-I) and melanoma-differentiation-associated gene 5 (MDA5). Mice with genetic defects in any of these individual RNA sensors, the receptor for IFN-a and -b, or constituents of its signaling cascade (e.g., STAT1) show markedly enhanced viral burden in tissues, which leads to rapid lethality.
Although IFN restricts infection, WNV has evolved countermeasures to limit its efficacy. Indeed, WNV is resistant to the antiviral effects of IFN in cell culture once infection is established. This may explain the relatively narrow therapeutic window for IFN administration that has been observed in animal models or humans infected with WNV [13] . WNV attenuates IFN function at multiple steps of the induction ( Figure 1A ) and signaling ( Figure 1B) cascade. (a) The WNV NS2A protein inhibits IFN-b gene transcription [14] . (b) WNV E and NS1 proteins independently inhibit IFN-b transcription in response to dsRNA [15, 16] . (c) Pathogenic WNV strains evade IRF-3-dependent signals without actively antagonizing the host defense signaling pathways [17] . This provides a kinetic advantage to elude the IFN response at early times after infection. WNV also targets the JAK-STAT proteins, essential elements of the IFN signaling pathway, to prevent the induction of antiviral genes. Thus, even when type I IFN is produced, it may not achieve its inhibitory effect. (d) WNV interferes with phosphorylation of JAK1 and Tyk2 [18] . (e) WNV infection actively promotes re-localization of cholesterol, which diminishes the formation of cholesterol-rich lipid rafts in the plasma membrane and attenuates the IFN signaling [19] . (f) The NS4B of WNV partially blocks STAT1 activation and IFNstimulated gene (ISG) induction [20] .
The Genetic Basis of Risk of Human WNV Infection Is Beginning to Be Understood
Most (,80%) human WNV cases develop without significant symptoms. Among clinically apparent cases, many experience a selflimited, although at times debilitating, febrile illness. A subset of WNV cases progress to paralysis, meningitis, and/or encephalitis.
Two human genes have been identified as susceptibility loci for WNV infection. (1) CCR5. Experiments in animals had established that chemokines direct leukocytes to the brain to clear WNV from infected neurons. In mice, a genetic deficiency of the chemokine receptor CCR5 was associated with depressed leukocyte trafficking, increased viral burden, and enhanced mortality [21] . Interestingly, analogous genetic deficiencies (e.g., CCR5D32, a deletion in the CCR5 gene) are associated with WNVinduced disease in humans [22] . Although individuals that are homozygous for the CCR5D32 allele represent about ,1% of the general United States population, 4%-8% of individuals with laboratory-confirmed symptomatic WNV infection were homozygous for the mutant allele. Thus, CCR5 functions as an essential host factor to resist neuroinvasive WNV infection, which may have implications for the use of CCR5 antagonists in HIV therapy. (2) OAS. In certain mouse strains, susceptibility to flaviviruses, including WNV, maps to a truncated isoform of the 29 59 oligoadenylate sythetase (OAS1b) gene, a member of an IFN-regulated gene family involved in degradation of viral RNA. A recent study suggests that a hypomorphic allele of the human ortholog OAS1 is associated with both symptomatic and asymptomatic WNV infection [23] . This data suggests that in humans, OAS1 is a genetic risk factor for initial WNV infection, although not for disease severity.
Conclusions
Pathogenesis and host immune response studies with model viruses (e.g., lymphocytic choriomeningitis, polio, herpes simplex, and mouse hepatitis viruses) created an impression that the virushost interface is remarkably conserved, and the paradigms generated for one pathogen are readily transferable to another. However, the complexity of individual viruses with respect to enzootic cycles, the host-pathogen-vector interface, cellular tropism, structural diversity, ability to induce injury, and immune system recognition and evasion has established that the exception is often the rule: the host responds differently to control individual viruses. Studies with WNV are continuing to educate us as to the extent of this complexity. Hopefully, these lessons will translate into novel therapeutics and vaccines against WNV and possibly, closely related pathogenic flaviviruses. 
